VALDIG Portal Vein Thrombosis Meeting
Hôtel de Ville de Paris
November 29th and 30th 2022
Organizing committee:
Laure Elkrief, Virginia Hernandez-Gea, Marco Senzolo and Pierre-Emmanuel Rautou
Day 1, November 29th 2022
8h30 – 8h50 Welcome of participants
8h50 – 9h: Opening and introductory words
9h – 12h30 Session 1: Non cirrhotic PVT
9h – 10h30
| Causes and underlying mechanisms | J Poisson, France |
| Impact of etiological therapy | C Bureau, France |
| Pathophysiology of portal hypertension in PVT without cirrhosis : similarities and differences with cirrhosis | JC Garcia Pagan, Spain |
10h30 – 11h Break
11h – 12h30
| Noninvasive tests versus liver biopsy? | L Elkrief, France |
| PSVD and PVT: two separate entities? | V Paradis, France |
| Anticoagulation in patients with recent and chronic PVT | A Plessier, France |
12h30 – 14h Lunch break
14h – 15h30 Session 2: PVT in patients with cirrhosis
| Epidemiology and risk factors | F Nery, Portugal |
| Impact treating the cause of cirrhosis | M Mandorfer, Austria |
| Anticoagulation in patients with cirrhosis to prevent and treat PVT and to prevent decompensation | A Albillos, Spain |
| When and how to treat PVT in a patient with simultaneous HCC (excluding PV invasion)? | M Senzolo, Italy |
| Management of PVT before and after liver transplantation |
F Durand, France |
15h30 – 16h Break
16h – 18h Session 3: Specificity of the portal venous system
| Specificity of the portal vein wall in cirrhosis (15 min + 15 min discussion) | V Hernandez-Gea, Spain |
| Specificity of the portal blood in cirrhosis (15 min + 15 min discussion) | Ton Lisman, The Netherlands |
| State of the art lecture : Immuno-thrombosis | Konstantin Stark, Germany |
Day 2, November 30th 2022
8h30 – 10h Session 4: Management of PVT without and with cirrhosis
| PVT and cirrhosis: what place for anticoagulation and for interventional radiology? |
D Tripathi, UK |
| PVT without cirrhosis: what place for anticoagulation and for interventional radiology? |
A de Gottardi, Switzerland R Salem, USA |
| Prevention and management of variceal bleeding in PVT without and with cirrhosis: should that really be the same as in cirrhosis? | D Patch, UK |
10h – 10h30 Break
10h30 – 12h30 Session 5: Specific issues in PVT without cirrhosis
10h30 – 11h30
| Impact on quality of life | A Baiges, Spain |
| Fertility, contraception and pregnancy | A Payancé, France |
| PVT in children: specificities as compared with adults | V McLin, Switzerland |
| Role of patient’s associations in student’s training | S Hullin, AMVF, France |
| Common discussion | |
11h30 – 12h30
| Portal cholangiopathy | A Shukla, India |
| Chronic abdominal pain, chronic enteropathy, mesenteric ischemia and intestinal necrosis | A Nuzzo, France |
| Symptomatic hypersplenism | S Sarin, India |
| Management of PVT in patients with pancreatic cancer and pancreatitis | M Primignani, Italy |
| Common discussion | |
12h30 – 13h30 Lunch break
13h30 – 18h Session 6: Consensus discussion : endpoints for studies in portal vein thrombosis
| Classification of portal vein thrombus extension | M Ronot, France |
| Classification of portal vein thrombosis evolution | P Northup, USA |
15h30 – 16h Break
| Timing of assessment | A Berzigotti, Switzerland |
| Goal of the treatment in patients with portal vein thrombosis | S Darwish Murad, the Netherlands |
17h30 – 18h Concluding remarks